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Abstract 
Cell-based high content phenotypic screenings are widely used in fundamental research, 
pharmaceutical industry, and healthcare to simultaneously evaluate the effects of multiple 
compounds or gene over-expressions/knockdown on the phenotype of cells. Most screenings, 
especially in the industrial sector, are performed using microplate technology, which relies on 
high reagents and cell consumption as well as on expensive liquid handling robotics. 
Developing miniaturized screening platforms has been an important topic in the past decade. In 
this study we demonstrate the applicability of the Droplet-Microarray platform based on 
superhydrophobic-superhydrophilic patterning for cell-based high throughput screenings. We 
show the homogeneous seeding of cells and culturing of different adherent cell lines in 
individual droplets of different sizes. We demonstrate pipetting-free medium exchange 
enabling cell cultures in miniaturized droplet arrays for up to 5 days. We establish the method 
of reverse transfection and reverse drug screenings in individual nanoliter-size droplets by 
printing the transfection mixtures or drug molecules directly onto superhydrophilic spots prior 
to cell seeding.  
 
Introduction   
 The high-throughput screening (HTS) of live cells is an immensely important method 
being increasingly applied in different scientific and industrial areas. It has raised the rate of 
scientific discoveries by enabling multiple parallel live cell experiments for the simultaneous 
evaluation of the effects of multiple factors on the phenotype of cells1, 2. Phenotypic cell-based 
screenings based on genetic perturbation of cells via RNA interference or gene over-expression 
are routine in fundamental science when investigating fundamental biological processes like 
cell signaling3, cell cycle control4, DNA repair machinery5, cell differentiation6, 7, apoptosis8, 9 
etc. HTS of live cells is widely employed in the pharmaceutical industry in fields such as drug 
discovery, antibody production and the toxicity testing of new drug candidates and bioactive 
compounds.   
Most cell-based HTS are performed in 96- and 384-well microplates. Microplate 
technology has been and remains accepted as the most reliable platform for cell-based assays, 
however, it has several drawbacks. First, it offers low throughput and therefore requires high 
number of microplates. Plates with higher capacity (1536- and 3456-well plates) are also used, 
but due to problems associated with handling minute volumes, employing such plates can raise 
the cost of screening10. Second, due to the relatively large sizes of individual wells, the plates 
are associated with high consumption of expensive reagents and valuable cells, making this 
valuable technology unaffordable for many research laboratories. In addition, requiring high 
quantities of cells makes it difficult or impossible to perform screenings on rare and hard-to-
expand cells such as primary and stem cells. This is critical in the field of healthcare, where a 
minute amount of patient material is available. One of the main problems of microplate 
technology is that it requires multiple pipetting steps and, therefore, depends on expensive fluid 
handling robotic systems that are incompatible with miniaturization and personalized medicine.  
In the past decade much has been done to miniaturize cell-based screenings by creating 
alternative platforms such as droplet microfluidic platforms11-15, DropArray of Curiox, 
SlipChip16-20, platforms based on hydrophobic-hydrophilic patterning21-23 and miniaturized 
microplates24-27. Droplet microfluidics enables generation up to a billion homogeneous droplets 
encapsulating cells. This technology is widely used in applications such as the detection of cell 
metabolites28, antibody screens29, PCR30 or sequencing14, 15, and is compatible with high 
throughput compound screens using the “droplet library”31. However, droplet microfluidic 
technology might be inefficient for smaller assays32; it does not have spatial indexing available 
as in two-dimensional arrays, thereby requiring the use of sophisticated bar coding to 
distinguish between droplets; it is incompatible with time lapse or end point microscopic 
analysis; and it makes it hard to study cells of adherent nature since they have no surface to 
interact with. SlipChip is an example of a microfluidic platform allowing the formation of two-
dimensional arrays and microscopic analysis16. It permits the easy parallel and homogeneous 
spreading of cells, relying on the pipetting of multiple compounds into microfluidic paths33. 
There are several groups utilizing hydrophobic-hydrophilic micropatterning to create arrays of 
cells encapsulated in droplets for screening applications21-23. These are innovative and 
promising platforms for miniaturized cell-based screenings, however, they are still not 
compatible with high throughput format.  
In 2001 Sabatini and colleagues developed cell microarrays and established a method of 
“reverse transfection”34, a system based on preprinting an array of transfection mixtures 
containing nucleic acid onto a glass slide, followed by seeding a monolayer of adherent cells 
onto the glass surface. Cells growing on printed areas uptake the nucleic acid, creating a cluster 
of transfected cells. This methodology allows for parallel transfection of up to 10.000 cell 
clusters per standard microscope slide. Cell microarray technology thus permits high 
throughput parallel gene over-expression or knockout experiments, low reagent and cell 
consumption, and easy, pipetting-free handling. Many research groups adopted this method for 
their scientific discoveries2, 4, 8, 9. Later applications of cell microarrays were extended to 
screenings of small drug like molecules. In this case drugs have to be embedded in polymer or 
lipids to prevent rapid diffusion of molecules into the media and ensure direct delivery of drugs 
into the cell cluster35, 36. The main limitation of cell microarray technology is the absence of 
barriers between spots and the culturing of cells in one medium, which leads to risk of cross-
contamination and paracrine interaction between cell clusters and restricts this technology to 
cells of adherent nature.   
Recently we demonstrated that superhydrophobic-superhydrophilic patterning could be 
used to form high density arrays of microdroplets (Droplet-Microarray (DMA) platform)37. We 
demonstrated the formation of droplet microarray using the effect of discontinuous dewetting38, 
the formation of arrays of hydrogel micropads38 and DMA Sandwiching Chip for the parallel 
addition of chemical libraries to the individual droplets37. 
In this work we demonstrated how to solve the problems of the live cell microarrays 
developed by Sabatini using the inherent compartmentalization capability of the DMA platform. 
We showed the possibility of culturing HEK293, HeLa and A549 cell lines in arrays of droplets 
of 3 to 80 nL and demonstrated a single-step, pipetting-free medium exchange enabling cell 
culturing in droplet microcompartments up to 5 days. We established the method of reverse 
transfection and reverse small molecule drug screenings in individual droplets on the DMA. 
This combination of the parallelization, compartmentalization and miniaturization opens the 
way to extend the applications of live cell microarrays to small molecule screenings, drug 
screenings, reduce possible contamination problem and solve the problem of cell migration 
between the individual microwells. 
 
Experimental 
 
Fabrication of DMA slides 
Preparation of superhydrophilic-superhydrophobic patterned surfaces was described 
elsewhere38. Briefly, patterns were prepared as stated below.  
Glass slide activation. Glass slides (Schott Nexterion, Jena, Germany) were activated 
by immersing in 1M NaOH (Carl Roth GmbH + Co. KG, Karlsruhe, Germany) for 1 hour 
followed by neutralization by immersing in 1M HCl (Merck KGaA, Darmstadt, Germany) for 
30 minutes, followed by washing with DI water. 
Glass slide modification. Activated glass slides were modified by spreading a small 
amount of 20% v/v ethanol solution of 3-(trimethoxysilyl)propyl methacrylate (Sigma-Aldrich, 
Munich, Germany) over activated glass slides and incubating them for 30 minutes, followed by 
washing with ethanol and drying under nitrogen stream. 
Glass slide fluorination. Glass slides were fluorinated by storing them overnight under 
50 mbar vacuum in a sealed desiccator containing an open 1,5 mL Eppendorf tube with 30 µL 
of trichloro(1H, 1H, 2H, 2H-perfluorooctyl)silane (Sigma-Aldrich, Munich, Germany).  
Polymer film preparation. To prepare a porous polymer layer, the following 
polymerization mixture was used: 24 wt.%  2-hydroxyethyl methacrylate (HEMA) (Sigma-
Aldrich, Munich, Germany), 16 wt.% ethylene dimethacrylate (EDMA) (Sigma-Aldrich, 
Munich, Germany), 12 wt.% 1-decanol, 48 wt.% cyclohexanol (Sigma-Aldrich, Munich, 
Germany) and 0,4 wt.%  2,2-dimethoxy-2-phenylacetophenone (Sigma-Aldrich, Munich, 
Germany). To control the thickness of the polymer layer, 1,86 µm monodispersed silica beads 
SiliaSphere 100Å (SiliCycle, Quebec, Canada) were applied on the corners of a fluorinated 
glass slide. Afterwards, the polymerization mixture was applied onto a fluorinated glass slide 
and covered with a modified slide. Polymerization occurred via UV irradiation of the glass 
mold with 260 nm UV light for 15 minutes at 7 mW/cm2 intensity. Polymerization and surface 
patterning were carried out on an OAI Model 30 deep-UV collimated light source (Optical 
Associates Inc., San Jose, CA) fitted with an USHIO 500 W Hg-xenon lamp (Ushio, Tokyo, 
Japan). The fluorinated glass slide was then removed and the polymer surface washed with 
ethanol and dried with an air gun. To increase the polymer surface’s roughness and therefore 
its hydrophobicity and hydrophilicity, the polymer’s smooth superficial layer was removed by 
applying an adhesive tape (EAN 4042448036223, Tesa, Offenburg, Germany) to its surface 
followed by rapid tape removal.  
Surface patterning. Prior to patterning, the surface was modified by incubating the slides 
in solution containing 45 mL of dichloromethane (Merck KGaA, Darmstadt, Germany), 56 mg 
of 4-(dimethylamino)pyridine (Novabiochem, Merck KGaA, Darmstadt, Germany), 111,6 mg 
of 4-pentynoic acid (Sigma-Aldrich, Munich, Germany) and 180 µL of N,N’-
diisopropylcarbodiimine (Alfa Aesar, Karlsruhe, Germany) for 4 hours under stirring at room 
temperature. A superhydrophobic pattern was created by applying 5% v/v solution of 1H, 1H, 
2H, 2H - Perfluorodecanethiol (Sigma-Aldrich, Munich, Germany) in acetone onto the polymer 
surface and irradiating the slide with 260 nm UV light at 7 mW/cm2 for 1 min through a quartz 
photomask (Rose Fotomasken, Bergisch Gladbach, Germany). The polymer surface was 
extensively washed with acetone and dried with an air gun. Superhydrophilic spots were then 
created by applying 10% v/v ß-mercaptoethanol (Alfa Aesar, Karlsruhe, Germany) solution in 
1:1 v/v water:ethanol onto the patterned surface and irradiating the slide with 260 nm UV light 
at 7 mW/cm2 for 1 min through a quartz slide.  
 
Formation of droplet microarrays (“rolling droplet” method).  
A large droplet of an aqueous solution was applied onto the patterned surface of a DMA 
slide (for 30 to 90 seconds in case of cell suspension) followed by slightly tilting of the slide, 
causing the droplet to roll off the surface spontaneously forming an array of separated droplets 
(Fig. 1b, Video S1). We refer to this method of forming a Droplet-Microarray as the “rolling 
droplet” method. SL spots on the DMA slide were divided into three fields surrounded by SH 
borders allowing for the application of a fixed volume of solution on one field, to ensure even 
droplets distribution across the slide and the experiment’s reproducibility. 
Measuring droplet heights and calculating volumes of the droplets. To measure droplet 
height, water was spread onto a DMA slide and images of droplets were taken from the side 
using a camera with the telecentric measuring lens 62-932 (Edmund Optics GmbH, Karlsruhe, 
Germany). To minimize evaporation, imaging took place at 95% relative humidity in a sealed 
chamber equipped with a humidifier (Conrad Electronic, Hirschau, Germany) and humidity 
sensor (Galltec, Bondorf, Germany). The droplets’ height in the middle and width at the bottom 
were measured in pixels using ImageJ software. Knowing the width of the droplet’s footprint 
(equaling the size of the SL spot), the pixels were converted to μm. The droplets’ approximate 
volume was calculated using the formula for volume of a spherical cap: (
𝜋ℎ
6
) (3𝑎2 + ℎ2), where 
h is height of the droplet and a is size of superhydrophilic spot (droplet footprint) divided by 
two.   
 Alternatively, we estimated droplet volume by spreading the water on the slide and 
weighing it. Each droplet’s volume was calculated by dividing the total weight by the number 
of droplets.  
    
Cell culture 
 Human embryonic kidney HEK293 cells, human cervical carcinoma HeLa cells and 
A549 cells were kindly provided by Dr. Olivier Kassel, Dr. Gary Davidson and Prof. Jonathan 
Sleeman (Institute of Toxicology and Genetics, KIT), respectively. HEK293, HeLa and A549 
cells were cultured in complete Dulbecco’s Modified Eagle’s Medium DMEM (Gibco, Life 
Technologies GmbH, Darmstadt, Germany) containing 10% of fetal bovine serum FBS (Sigma-
Aldrich, Munich, Germany) and 1% of Penicillin/Streptomycin (Gibco, Life Technologies 
GmbH, Darmstadt, Germany). Cells were trypsinized using 0,25% trypsin/EDTA (Gibco, Life 
Technologies GmbH, Darmstadt, Germany) and split every 2-3 days at a ratio of 1/10 for 
HEK293 and A549 cells and 1/7 for HeLa cells, respectively.   
Before seeding cells on DMA slides, the surfaces were prepared as follows. Patterns 
were sterilized in ethanol, dried and immersed in DMEM medium containing 1% FBS and 1% 
Penicillin/Streptomycin and incubated for 1 hour in a cell culture incubator at 37ºC. Medium 
was aspirated and slides were dried for 1 hour under sterile hood. Afterwards, superhydrophilic 
spots were coated with 2,2% wt gelatin/water solution (Sigma-Aldrich, Munich, Germany). 
Patterns were incubated in cell culture incubator for 1 hour and dried under the sterile hood for 
45 minutes. After preparation, slides could be used immediately or stored for up to three days 
in the fridge. To avoid droplet evaporation, the chamber for cell culturing was pre-humidified 
30 minutes before starting an experiment according to the following procedure. For each DMA 
slide a sterile 100 mm Petri dish was placed inside another 150 mm Petri dish containing 10 
mL of PBS and paper tissues placed along the circle of the dish. Such double Petri dishes were 
placed in cell culture incubator as a vertical stack and covered with sterile wetted paper tissues. 
Prior the cell seeding step, the double dish was taken out of an incubator and a preconditioned 
DMA slide was placed inside the sterile 100 mm Petri dish. Cells were seeded on the array field 
surrounded by the superhydrophobic border on a DMA slide by applying 1.7 mL of cell 
suspension containing the desired cell concentration (Table 1) (Fig. 1a). The Petri dish lid was 
closed to minimize evaporation and cells were allowed to settle for 30 seconds for HeLa and 
90 seconds for HEK293 and A549 cells. Afterwards, the Petri dish with closed lid was slightly 
tilted to allow the cell-suspension droplet to roll off the surface of the DMA slide, leading to 
the spontaneous formation of droplets containing cells. The double Petri dish with DMA slide 
containing cells was immediately returned back to the stack in the cell culture incubator. The 
paper tissues covering the stack of double Petri dishes were wetted every day to keep local 
humid environment constant and prevent evaporation of the droplets.    
 
Table 1. Seeding concentrations of cells used to achieve optimal initial cell density for cell 
proliferation and viability on DMA. 
Spot size 
Cell type 1000 µm 500 µm 350 µm 
HEK293 15x104 cells/ mL 20x104 cells/ mL 20x104 cells/ mL 
HeLa 25x104 cells/ mL 50x104 cells/ mL 100x104 cells/ mL 
A549 15x104 cells/ mL 20x104 cells/ mL 50x104 cells/ mL 
 
 
Studying the homogeneity of cell seeding 
 HeLa cells were seeded onto a DMA slide as described above and cultured in droplets 
for 5 hours to allow cells to attach to the surface. Afterwards, cells were fixed and stained by 
immersing the slide in a solution containing 3,7% formaldehyde, 0,1% triton, 0,5 µg/mL DAPI 
in Dulbecco’s phosphate buffered saline containing CaCl2 and MgCl2 (DPBS/CaCl2/MgCl2) 
(Gibco, Life Technologies GmbH, Darmstadt, Germany) for 15 minutes at room temperature. 
The slide was then mounted with Immu-Mount (Thermo Fisher Scientific Inc., Darmstadt, 
Germany) and dried at +4ºC. Images of each individual droplet were taken with an automated 
screening Olympus IX81 microscope (Olympus, Tokyo, Japan). DAPI stained nuclei were 
counted using CellProfiler (http://www.cellprofiler.org/).    
   
Viability and cell growth study  
All images for this study were taken using a Keyence BZ-9000 microscope (KEYENCE, 
Osaka, Japan). For proliferation and viability study, cells were seeded onto a DMA slide and 
ten spots were imaged immediately to estimate initial cell concentration. Afterwards, the same 
spots were imaged every 24 hours for up to 96 hours of culturing. Cells were counted manually 
using brightfield microscopy images. To distinguish between live and dead cells, HeLa cells 
were cultured in medium containing 100 nM Propidium Iodide (PI) (Invitrogene, Merelbeke, 
Belgium) to stain dead cells. In a separate experiment we confirmed that there was no difference 
in the growth and viability of HeLa cells with and without PI staining (data not shown). For 
HEK293 and A549 cell lines, cells showing well spread morphology were counted as live cells 
and those possessing round and shrunk morphology were considered as dead/apoptotic cells. 
The accuracy of such manual quantification was validated using double Calcein/PI staining. 
Each experiment was repeated at least three times. 
Growth rates of HEK293, A549 and HeLa cells in 24 well plates were estimated as 
follows. Cells were plated in a 24-well plate with surface cell densities corresponding to those 
of a 1000 µm DMA slide, which were 90.500, 31.800 and 80.000 cells per well for HEK293, 
HeLa and A549, respectively. Every 24 hours, cells were detached from the surface with trypsin 
and counted using a hemocytometer (Assistant, Sondheim/Rhoen, Germany).   
 
Reverse transfection 
 The following transfection mixture was prepared in a 384-well plate: 2.75 µL of 
ScreenFect Dilution Buffer (Incella GmbH, Eggenstein-Leopoldshafen, Germany) containing 
0.4 M sucrose (Carl Roth GmbH, Karlsruhe, Germany), 6.25 µL 300 ng/µL pCS2-H2B-GFP 
or pCS2-H2B-RFP in water (kindly provided by Dr. Gary Davidson, Institute of Toxicology 
and Genetics, KIT), 5 µL ScreenFect®A (Incella GmbH, Eggenstein-Leopoldshafen, Germany) 
and 4.65 µL ScreenFect Dilution Buffer. The mixture was incubated for 20 minutes at room 
temperature to allow formation of lipoplexes. Afterwards, 3.75 µL of 0.1% solution of 
fibronectin in water (VWR International GmbH, Germany) and 7.5 µL of 0.2% solution of 
gelatin in water (Sigma-Aldrich, Munich, Germany) were added to the mixture. Then the 
transfection mixture was printed onto the DMA slide’s SL spots using a sciFLEXARRAYER 
S11 liquid dispenser (Scienion, Berlin, Germany) in amounts of 20 nl, 40 nl and 150 nl for 
DMA slides with spots measuring 350 µm, 500 µm, and 1000 µm, respectively. Slides were 
dried in a closed desiccator containing silica gel (Sigma-Aldrich, Munich, Germany) for 2 days 
in case of 350 and 500 µm spot sizes, and for 5 days in case of the 1000 µm spot size. Cells 
were seeded onto the DMA slide with preprinted transfection mixtures as described above. 
Transfection efficiency was estimated 24 and 48 hours after seeding by live imaging.  
 
“Reverse” drug treatment 
Water solution of doxorubicin (European Pharmacopolia Reference Standard, EDQM, 
Strasbourg, France) was printed onto the SL spots on DMA slides using a sciFLEXARRAYER 
S11 liquid dispenser (Scienion, Berlin, Germany) in amounts 25, 7, 5, 3, 2 ng per spot. DMA 
slides with preprinted drug were dried in a sealed desiccator containing silica gel (Sigma-
Aldrich, Munich, Germany) for 24 hours. Cells were seeded onto DMA slides containing 
doxorubicin as described above. The effect of doxorubicin was evaluated 24 hours after seeding 
via live staining with Calcein AM (Life Technologies GmbH, Darmstadt, Germany). Staining 
was done by “sandwiching” a DMA slide containing cells with an identical pattern, where 50 
µM solution of Calcein AM in Dulbecco’s Phosphate Buffered Saline containing CaCl2 and 
MgCl2 (DPBS/CaCl2/MgCl2) (Gibco, Life Technologies GmbH, Darmstadt, Germany) was 
spread, for 10 minutes. Slides were then separated, and the DMA slide placed in a cell culture 
incubator for 15 minutes. Images of treated spots were taken using the Keyence BZ-9000 
microscope (KEYENCE, Osaka, Japan). The number of live cells stained green was counted 
using CellProfiler (http://www.cellprofiler.org/).  
 
Results  
 
Droplet-Microarray Reverse Screening Platform 
The design of a Droplet-Microarray (DMA) slide is shown in Fig. 1a. A standard 
microscope glass slide was covered with a nanoporous poly(2-hydroxyethyl methacrylate-co-
ethylene dimethacrylate) (HEMA-EDMA) film and esterified using 4-propynoic acid. The 
porous DMA surface was then functionalized via thiol-yne reaction with 2-mercaproethanol to 
make differently-sized superhydrophilic (SL) square spots and with perfluorodecanthiol to 
make supehydrophobic (SH) borders of corresponding sizes (Fig. 1a).39 The DMA slides 
contained 588, 2187 or 4563 SL spots per slide in case of spots measuring 1000 µm, 500 µm 
and 350 µm, respectively. Because of the extreme difference in wettability between SL (static 
water contact angle 4.4o) and SH (static water contact angle 170o), SL spots can be filled with 
water-based solution in a single step via the effect of discontinuous dewetting (Fig. 1 b-c)37-40. 
Here the ability to create thousands of separated aqueous micro-compartments in a single step 
was used to establish and evaluate the DMA for reverse cell screening applications (Fig. 1c).  
The screening pipeline using DMA is depicted in Fig. 1c. First, substances of interest 
such as drugs or transfection mixtures are printed onto SL spots using a conventional non-
contact liquid dispenser and dried. To start a cell screen, a pre-printed SH-SL slide is used to 
form an array of separated microdroplets in one step via the “rolling droplet” method (Fig. 1c, 
Video S1, experimental part). Once droplets have formed, the preprinted chemicals dissolve in 
the individual microdroplets containing live cells, leading to changes in their phenotype that 
can be analyzed using conventional techniques such as fluorescence microscopy or array 
scanners. As shown in Fig. 1c, in case of adherent cells, DMA slides can be fully immersed into 
a solution for washing, staining or fixation procedures. On the other hand, each droplet can be 
also treated individually by applying the sandwich method when staining, washing, or fixation 
solution is spread onto identical DMA slide and then added to droplets containing cells by 
sandwiching37 (Fig. 1c). This is important, for example, when using non-adherent cells where 
each droplet’s content must be preserved. As a final step, phenotype changes in cells are 
analyzed using fluorescence microscopy (Fig. 1c). 
 
Homogeneous droplet formation and cell seeding on DMA 
The pipetting-free homogeneous formation of thousands of droplets in array format is 
indispensable for various screening applications whereby substances, particles, or cells must be 
evenly distributed between compartments. To monitor the distribution of droplet volumes, we 
imaged water droplets formed on a DMA slide from the side to measure their heights (Figs. 2a, 
b). As Fig. 2a illustrates, the droplets’ heights measured 195±25, 90±23 and 64±10 µm for 
patterns with 1000 µm, 500 µm and 350 µm spots, respectively. Using the equation of the 
volume of spherical cap, volumes of droplets formed in 1000, 500 and 350 µm SL spots were 
estimated to number 81±18, 9.3±2 and 3.25±0.5 nL, respectively. This estimation was 
confirmed by measuring the droplets’ average volume by weighing water spread on a DMA 
slide containing a certain number of formed droplets. This method yielded very similar droplet-
volume values (84.5±14, 9±1 and 3.4±0.2 nL for 1000, 500 and 350 µm SL spots, respectively).   
In the next step we investigated the possibility of creating an array of homogeneously 
distributed cells in droplets. Human cervical carcinoma cells (HeLa) were seeded onto a DMA 
slide using the “rolling droplet” method (experimental part) and incubated for several hours to 
allow cells to attach to the surface. To calculate the number of cells in each droplet, cells were 
fixed, stained with DAPI, and subjected to automated microscope imaging and analysis (Fig. 
2c-e). Droplets contained 163±33, 57±17 and 26±16 cells for DMAs with spot sizes of 1000, 
500 and 350 µm, respectively (Figs. 2c-e). Color-coded maps of distribution of cell numbers 
reveal that cells were spread randomly across the slide (except the corner spots), that the number 
of cells per droplet did not depend on the position on the field, and was unaffected by the cell-
spreading technique (Figs. 2c-e). We observed spots containing less than 10 cells on DMA with 
350 µm spot size, which can be explained by inhomogeneity of the initial cell suspension and 
small volume of the droplets.   
 
Cell culturing on Droplet-Microarray  
To evaluate the DMA platform for cell-based screening we optimized culturing 
conditions in individual droplets using three common cell lines: a human cervical cancer cell 
line (HeLa), human embryonic kidney cell line (HEK293), and human lung adenocarcinoma 
epithelial cell line (A549). To prepare the DMA slide to culture cells, we first immersed it in 
DMEM medium containing 1% FBS, followed by coating SL spots with 2.2% wt. gelatin. 
Droplet microarray was formed and the array was placed in a cell culture incubator in a 
humidified double Petri dish to prevent evaporation. All three cell lines cultured in individual 
droplets of different sizes for 24 hours revealed spread morphology similar to that of cells 
cultured in microplates (Fig. 3) and viability of cells in droplets was 97-100% as proven by 
live/dead staining (Fig. S1e). 
For screening applications where the effect of chemicals on cell phenotype might 
develop in hours or days, it is important to be able to culture cells for several days. To observe 
how long cells can be cultured on DMAs without medium exchange, we monitored cell viability 
and the growth rates of HEK293, A549 and HeLa cells cultured in individual droplets of 
different sizes for five days (Fig. 4, Fig. S2). We noted that the rate of cell growth depended 
strongly on the initial cell concentration (Fig. S1a). We therefore experimentally defined the 
initial cell concentration for optimal cell growth for each cell line (Table 1). As demonstrated 
in Fig. 4b-d, cells proliferated for up to 48 hours on 1000 µm pattern and up to 24 hours on 500 
µm and 350 µm patterns. All three cell lines grew slower in individual droplets compared to a 
24-well microplate (Fig. S1d). This can be explained by the fact that the volume of medium per 
cell is approximately 30 times lower in droplets than in a well in a 96-well plate with the same 
density of cells per area. Nevertheless, the viability of cells in droplets after 24 hours of 
culturing ranged from 95 to 100% depending on the cell line and spot size, similar to the 
viability of cells in microplates (Fig. S1e). Depending on cell line, viability of cells after 48 
hours of culturing was 86-100%, 69-97% and 63 to 100% on DMA with spot sizes 1000 µm, 
500 µm and 350 µm spot sizes, respectively (Fig. S1e).   
As a next step we explored the potential of medium exchange on the DMA platform. 
Medium exchange is usually difficult in miniaturized cell screening systems, such as droplet 
microfluidics. The DMA platform is an open system, contrary to most of the microfluidic 
systems and, therefore, medium can be easily exchanged using the “rolling droplet” method 
(Fig. 4a, Video S1). Briefly, 1,7 mL of fresh medium was applied onto one of three fields on a 
DMA slide, followed by tilting the slide slightly to allow the medium to roll off the surface, 
thereby forming individual droplets with fresh medium. As depicted in Fig. 4 b-d, medium 
exchange prolonged cell proliferation inside the droplets for up to 96 hours (Fig. 4b-d). 
Although the growth rate of HeLa cells in droplets was still lower than in microplates, cells 
remained high viability comparable with that of cells cultured in microplates (Fig. 4b-d). 
Considering these factors together, we can conclude that it is possible to perform screening of 
live cells using the DMA platform with 1000 µm, 500 µm and 350 µm spot sizes for up to 48 
hours without medium exchange and for up to 96 hours in case of daily medium exchange. 
 
Reverse Cell Transfection and Drug Screening 
High-throughput gain- or loss-of-function cell experiments are key to understanding 
gene and protein functions2, 4, 8, 9. Most of such HTS experiments are performed either using 
standard microplates or using Sabatini´s reverse cell transfection arrays. Combining the 
compartmentalization advantage of the DMA with the high throughput and the pipetting-free 
nature of the reverse cell transfection method would be beneficial to extend the scope of the 
reverse transfection to other cell screen types. Here, we optimized the method of reverse 
transfection using the DMA platform. Transfection mixtures containing transfection reagent, 
plasmid DNA expressing H2B-YFP or H2B-RFP, buffer and gelatin were printed onto SL spots 
using a non-contact liquid dispenser (Fig. 5a). Slides were dried in a desiccator for 3 days and 
5 days in case of 1000 µm and 500/350 µm spots, respectively. HEK293 cells were seeded on 
the DMA slide to create an array of droplets, and transfection efficiency was assessed 24 hours 
after seeding using fluorescence microscopy (Fig. 5). HEK293 cells were successfully 
transfected with plasmids expressing H2B-YFP and H2B-RFP with transfection efficiency 
from 50 to 80% (Fig. 5). For comparison the transfection efficiency of ScreenFect transfection 
reagent in 96 well plate using conventional transfection protocol is from 60 to 90%. As shown 
on Fig. 5b, there was no cross-contamination between the spots during the seeding procedure, 
although the superhydrophobic gap between the SL spots measured only 175 µm for the 350 
µm array. 
Previously we demonstrated the parallel simultaneous addition of drugs into individual 
droplets on a DMA slide using the “sandwiching method”37. In this study we introduced small-
molecule drugs to individual droplets using a “reverse” approach by pre-printing chemicals 
onto SL spots before an experiment. To prove the absence of cross-contamination between spots 
during the seeding procedure, a water solution of the antineoplastic drug doxorubicin was 
printed onto SL spots on DMA slides with three different spot sizes in a checkerboard pattern 
amounting to 25 ng per spot. Slides were dried in a desiccator overnight, and an array of droplets 
was formed using the “rolling droplet” method by applying 1.7 mL of water for 30 seconds, 
then slightly tilting the slide to make the big droplet roll off the surface, thus forming the droplet 
array (Fig. 6a, Video S1). Fluorescence images of the slide before and after droplet array 
formation (Fig. 6b-c, Fig. S3) confirmed that there was no cross-contamination between the 
spots in conjunction with water solution of doxorubicin, even for 350 µm spots with only 175 
µm SH barriers. 
In the next step, we introduced HeLa cells to doxorubicin using the “reverse approach”. 
Doxorubicin was pre-printed onto the DMA slide with 1000 µm hydrophilic spots in a 
checkerboard pattern (25 ng per spot). HeLa cells were seeded onto this slide using the “rolling 
droplet” method. The drug’s effect was quantified 24 hours after treatment by Calcein staining. 
As shown in Figs. 7a and b, spots with printed doxorubicin contained few or no live cells. In 
contrast, spots without doxorubicin were full of live cells (Figs. 7b and c). Cell viability is 
quantified in Fig. 7d. To exclude the influence of doxorubicin on cells cultured in neighboring 
spots not containing the drug, we compared the viability of cells in those droplets with that of 
cells on a slide not containing the drug. Figure 7d reveals that there was no difference in the 
number of live cells on these two DMAs, confirming that cross-contamination between droplets 
during the seeding procedure or culturing period does not occur (Fig. 7d). To prove that we can 
control concentration of doxorubicin in droplets, HeLa cells were introduced to doxorubicin 
preprinted in amounts ranging from 2 to 7 ng per spot, resulting in the final concentration of 
doxorubicin in droplets ranging from 46 to 161 µM. Figure 7e demonstrates the concentration-
dependent effect of doxorubicin on the viability of HeLa cells. IC50 of doxorubicin calculated 
based on these results equals 63.9 µM. We previously showed that the IC50 value of 
doxorubicin on HeLa cells determined using the same experimental setup (cell density per area 
and incubation time with the drug) in 96 well plates was 3 µM37. The increase of IC50 in the 
droplet microarray system can be explained by higher “culture medium volume” to “cell 
number” ratio in microplates compared to the droplet microarray system. In other words, 
although the concentration of doxorubicin was the same in the droplets and in the microwells, 
the total amount of the drug per single cell was significantly lower in the case of the droplet 
microarray platform. In general IC50 value of a drug can vary significantly depending on 
experimental setup: according to the literature IC50 value of doxorubicin in HeLa cells was 
found to be 0.2 µM41, 3.7 µM42 and 16.7 µM43. 
 
Discussion and conclusion 
In current study we explored the potential of Droplet-Microarray as a miniaturized 
technology for high content cell-based screens and demonstrated the suitability of the platform 
for cell-based screening applications.  
We fabricated arrays containing square superhydrophilic spots with side lengths of 1000 
µm, 500 µm and 350 µm, which could trap droplets of 80, 9 and 3 nL, respectively, which 
require 1000, 10.000 and 30.000 times less medium and reagents comparing to 96-well 
microplates and about 600, 5.000 and 15.000 times less medium and reagents comparing to 
384-well microplates. Each spot has a 30- (1000 µm), 130- (500 µm) and 260- (350 µm) times 
smaller surface area compared to wells in a 96-well microplate, which is reflected in lower cell 
consumption for a single experiment. In addition to minute reagent and cell consumption DMA 
offers higher throughput. For comparison one DMA with the same area as microtiter plate can 
contain from 3.500 to 29.000 spots depending on spot size, which means that one DMA can 
potentially substitute up to 75 384-well plates. Thus, due to minute reagent consumption and 
higher throughput, DMA allows for dramatic decrease in the total cost of cell screening 
experiments.   
The minimal variation in initial condition is important for achieving reliable screening 
data and we were able to demonstrate that Droplet-Microarray created by spontaneous droplet 
formation has homogeneous distribution of droplet volumes and cell numbers between droplets. 
It should be noted that variation in initial cell densities per droplet was higher in smaller droplets 
(350 µm) if compared to bigger droplets (1000 µm). Initial cell number can be a critical 
parameter and therefore the spot size should be carefully validated for particular screening and 
read-out protocols.  
We demonstrated the culturing of different adherent cell lines in individual droplets of 
different sizes. Pipetting-free medium exchange enabling cell cultures in miniaturized droplet 
arrays for up to 5 days was introduced. We demonstrated that cells proliferated on a DMA for 
up to 48 hours without medium exchange and up to 96 hours in case of medium exchange. 
Medium exchange is a challenge for most of the miniaturized cell compartmentalization 
technologies. The advantage of the DMA platform is that the system is open and, thus, facile 
medium exchange is possible by the rolling droplet method (Fig. 4a). In should be noted though 
that exchange of the medium requires coverage of the whole slide with medium for a few 
seconds, which can potentially lead to washing off dead or semi-adherent cells and might lead 
to cross-contamination. Therefore medium exchange would not be compatible with some 
protocols. In this case DMA can be used for protocols requiring up to 48 hours. Considering 
that many screening protocols (including drug screenings, gene-overexpression and gene 
silencing) are carried out within 24 to 48 hours2, 4, 8, 9, DMA can be a suitable platform for 
various screening applications. 
We demonstrated the applicability of the DMA platform for reverse cell transfection 
and reverse drug screenings in individual droplet microcompartments formed by discontinuous 
dewetting. The main advantage of the DMA platform compared to cell microarrays is screening 
of cells in completely separated micro compartments, which eliminates the problem of cross-
contamination and paracrine interaction between spots during the culturing period; and enables 
the screening of cells of non-adherent nature. Thereby, we combined the compartmentalization 
advantage of the DMA with the high throughput and the pipetting-free nature of the method of 
reverse cell transfection. Such unique combination enables us to extend the scope of the reverse 
transfection to broader cell screening applications.  
Routine low- to medium-throughput screenings are often performed manually using 
microplates and without the help of pipetting robots. The use of the DMA platform in such 
cases can make these experiments much faster and significantly cheaper. The initiation of a 
screening is performed simultaneously with the cell seeding step on a DMA slide and takes 
only several seconds. In case of using microtiter plate every well has to be pipetted individually 
first to seed cells and then to add chemical compounds. Using 384-well plate it might take 
several minutes to seed cells using a 16-chanel pipette and about an hour to initiate the screening. 
In addition, manual pipetting is associated with higher well-to-well variations. Finally, there is 
a time gap between seeding cells and initiation of a screen in the first well of the first plate and 
the last well of the last plate, which can affect the outcome of the screening especially in case 
of short incubation times. In pharmaceutical companies screenings are performed with the help 
of robotics, where the well-to-well variations are minimized and the protocols are well 
established. The costs of establishing a new screening system must be taken into account when 
considering switching to a miniaturized technology. However,  considering that big companies 
screen about 100.000 compounds a day10, the dramatic reduction of the total cost of experiments 
can be still beneficial when switching to a new system. 
Due to low cell consumption Droplet-Microarray can be used for performing screenings 
of rare and difficult to expand cells, such as primary or stem cells. Such screens can be useful 
for research purposes as well as in healthcare and can be difficult or impossible to perform 
using standard microplates. One example of such a screen is the drug sensitivity and resistance 
assay based on testing patient´s tumor cells against a library of anti-cancer compounds to predict 
optimal therapy for this particular patient44-46. Such assays performed in 96- or 384-well plates 
are restricted because of the limited patient´s tumor cell material available. The DMA platform 
carries a potential to be applied in such tests since it enables screenings of minute amounts of 
tumor cells and at the same time it is compatible with screening of larger chemical libraries.    
In summary, DMA screening platform enables (1) miniaturization (1000 times less 
reagent consumption than a regular 96-well plate); (2) high-throughput (up to 4.500 spots per 
microscope slide); (3) compartmentalization (no cross-contamination or paracrine interaction 
between spots; compatibility with both adherent and non-adherent cells) and (4) simultaneous 
pipetting-free cell seeding and initiation of screening. As any new technology Droplet-
Microarray needs to go through proof-of-concept initial phase to evaluate, validate and improve 
a technology as well as demonstrate its potential applications. We believe that Droplet-
Microarray platform has a great potential to be commercialized and become available to any 
biological lab. In this case the ready-to-use DMA slides with custom preprinted chemical 
libraries would be purchased and screening would be affordable and easy to perform. We 
believe that for curtain applications it will become easier and cheaper to perform cell-based 
high-throughput screenings using DMA technology than it is now using microtiter plates.    
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Fig. 1 Droplet-Microarray (DMA) reverse cell screening platform. (a) Schematic representation 
of a DMA slide and a table showing sizes of superhydrophilic spots and corresponding 
superhydrophobic borders. (b) Photographs of droplet microarrays. Scale bar 1 mm. (c) 
Schematic diagram of the workflow of reverse cell screening using DMA platform. 
  
 
Fig. 2. Homogeneity of droplet formation and cell seeding on DMA. (a) Heights and volumes 
of water droplets on DMA with different spot sizes. (b) Lateral images of water droplets on 
DMA with different spot sizes. Scale bar, 1 mm. (c-d) Color-coded maps showing spatial 
distribution of cells between droplets and graphs showing distribution of cells on Droplet-
Microarray containing 14x14 spots of 1000 µm size (c), 27x27 spots of 500 µm size (d) and 
39x39 spots of 350 µm size (e). Numbers in squares represent number of cells per droplet. Bold 
square on color-coded map define area of the slide suitable for analysis.   
 
 
 
Fig. 3 Microscope images of HEK293, A549 and HeLa cells cultured in droplets of different 
sizes for 24 hours. Scale bar 100 µm.  
 
Fig. 4 Growth rate and viability of HeLa cells cultured using Droplet-Microarrays with different 
spot sizes. (a) Schematic diagram of medium exchange on Droplet-Microarray. (b-d) Growth 
rate and viability of HeLa cells cultured on Droplet-Microarray with spot sizes 1000 μm (b), 
500 μm (c) and 350 μm (d). Graphs are showing growth rate of cells without (left) and with 
(middle) medium exchange and comparison of cell growth rates with and without medium 
exchange (right).  
 
 Fig. 5 Reverse cell transfection using Droplet-Microarray. (a) Schematic diagram of 
experimental workflow. (b) Fluorescence microscope images of HEK293 cells transfected with 
pCS2-H2B-YFP (green) or pCS2-H2B-RFP (red) on Droplet-Microarray with 1000 µm (top) 
and 500 µm (bottom) spot size in a checkerboard pattern. (c) Microscope images of individual 
droplets containing HEK293 cells transfected with pCS2-H2B-YFP (green) or pCS2-H2B-RFP 
(red) on DMA slides with different spot sizes (1000 µm, 500 µm and 350 µm).  
 
 
 
Figure 6. Cross-contamination study. (a) Schematic diagram of experimental workflow. (b, c) 
Microscopic image of DMA slide with spot sizes of 350 µm containing pre-printed doxorubicin 
in water solution (red) and fluorescence line profile of lines 1 and 2 indicated on the 
corresponding microscope image before DMA formation (b) and after DMA formation (c) 
Scale bar 500 µm.  
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 Figure 7. Treatment of cells with doxorubicin on Droplet-Microarray. (a) Schematic diagram 
of experimental workflow. (b) Microscopic images of calcein staining of HeLa cells 24 hours 
after seeding on Droplet-Microarray with preprinted doxorubicin (shows in red) in 
checkerboard pattern. (c) Microscopic images of calcein staining of individual doxorubicin 
positive and negative droplets containing HeLa cells 24 hours after seeding. (d) Comparison of 
the number of live cells in droplets on a negative control (NC) slide (one that contained no 
preprinted doxorubicin), in doxorubicin-negative droplets and doxorubicin-positive droplets.  
(e) Concentration-dependent effect of doxorubicin on viability of HeLa cells. 
 
 
 
 
